RFA-DA-23-014: Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on August 11, 2022.
From the official notice on Grants.gov, last changed March 21, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeDP1
- Clinical trialsNot allowed
- Funded byNIDA
- Median yearly award$484,500
- Typical project length5 years
- DP1, NIH Director's Pioneer Award. Support for an exceptionally creative scientist's high-risk, high-impact ideas. Other open DP1 notices.
Projects funded under RFA-DA-23-014 were run by National Institute on Drug Abuse (NIDA, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-23-014 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-DA-24-007 | October 20, 2022 | Closed August 7, 2025 | Closed |
Key dates
| Posted | March 21, 2022 |
|---|---|
| Deadline | August 11, 2022 |
| Archived by Grants.gov | September 16, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
oThe goal of this FOA is to attract outstanding early-stage investigators to the field of chemistry and pharmacology of substance used disorders. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. In recent years, there have been significant advances in methods and technologies for the identification of novel targets, mechanisms, and pathways of interest to substance use disorders and in identification of probes and optimized compounds for developing novel therapeutic agents. This FOA is to enable investigators with knowledge in the emerging chemical, pharmacological, and drug discovery technologies to pursue innovative and transformative research on chemical and pharmacological aspects of substance use disorders.
Funded under RFA-DA-23-014 so far
NIH funded 5 projects under RFA-DA-23-014 in fiscal 2023 to 2026, at 5 institutions. The median yearly award was $484,500.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| The neuropharmacology of brain activation during stages of drug abuse | Massachusetts General Hospital | 2026 | $501,000 |
| New Technologies for Accelerating the Discovery and Characterization of Neuroactives that Address Substance Use Disorders | University of California, San Francisco | 2026 | $484,500 |
| Developing a computational platform for induced-fit and chemogenetic drug design | Vanderbilt University | 2026 | $475,500 |
| Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants | High Point University | 2026 | $447,000 |
| Mitochondrial signaling dynamics in cocaine use disorder | Research Triangle Institute | 2026 | $665,570 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-23-014 still open?
No. It closed on August 11, 2022.
Who can apply for Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)?
Closed August 11, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-DA-23-014?
NIH RePORTER lists 5 projects funded under RFA-DA-23-014 in fiscal 2023 to 2026, at 5 institutions. The most were at Massachusetts General Hospital, University of California, San Francisco, Vanderbilt University.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- NIH Director's Pioneer Award (DP1 Clinical Trial Optional)
- Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)